De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Aurobindo Pharma Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Aurobindo Pharma heeft een totaal eigen vermogen van ₹298.5B en een totale schuld van ₹66.5B, wat de schuld-eigenvermogensverhouding op 22.3% brengt. De totale activa en totale passiva bedragen respectievelijk ₹450.7B en ₹152.2B. De EBIT Aurobindo Pharma is ₹47.8B waardoor de rentedekking 139.5 is. Het heeft contanten en kortetermijnbeleggingen van ₹63.3B.

Belangrijke informatie

22.3%

Verhouding schuld/eigen vermogen

₹66.48b

Schuld

Rente dekkingsratio	139.5x
Contant	₹63.26b
Aandelen	₹298.51b
Totaal verplichtingen	₹152.21b
Totaal activa	₹450.72b

Recente financiële gezondheidsupdates

Recent updates

Estimating The Intrinsic Value Of Aurobindo Pharma Limited (NSE:AUROPHARMA)

Sep 10

This Is Why Aurobindo Pharma Limited's (NSE:AUROPHARMA) CEO Can Expect A Bump Up In Their Pay Packet

Aug 23

Earnings Update: Here's Why Analysts Just Lifted Their Aurobindo Pharma Limited (NSE:AUROPHARMA) Price Target To ₹1,422

Aug 13

Here's Why Aurobindo Pharma (NSE:AUROPHARMA) Can Manage Its Debt Responsibly

Jun 20

Aurobindo Pharma Limited (NSE:AUROPHARMA) Released Earnings Last Week And Analysts Lifted Their Price Target To ₹1,271

May 29

Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value

May 22

Aurobindo Pharma Limited's (NSE:AUROPHARMA) Earnings Are Not Doing Enough For Some Investors

Apr 10

Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Worth ₹1.1k Based On Its Intrinsic Value?

Jan 14

Aurobindo Pharma (NSE:AUROPHARMA) Has A Pretty Healthy Balance Sheet

Dec 27

Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value

Sep 07

Is Aurobindo Pharma (NSE:AUROPHARMA) A Risky Investment?

Jun 14

Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Trading At A 29% Discount?

May 21

Aurobindo Pharma Limited's (NSE:AUROPHARMA) Intrinsic Value Is Potentially 93% Above Its Share Price

Feb 11

Aurobindo Pharma (NSE:AUROPHARMA) Seems To Use Debt Quite Sensibly

Jan 09

Is There An Opportunity With Aurobindo Pharma Limited's (NSE:AUROPHARMA) 50% Undervaluation?

Nov 02

We Think Aurobindo Pharma (NSE:AUROPHARMA) Can Stay On Top Of Its Debt

Jun 20

Calculating The Intrinsic Value Of Aurobindo Pharma Limited (NSE:AUROPHARMA)

Apr 14

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( ₹242.1B ) AUROPHARMA } overtreffen de korte termijn passiva ( ₹122.0B ).

Langlopende schulden: De kortetermijnactiva AUROPHARMA ( ₹242.1B ) overtreffen de langetermijnschulden ( ₹30.2B ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: De netto schuld/eigen vermogen ratio ( 1.1% ) AUROPHARMA wordt als voldoende beschouwd.

Schuld verminderen: De schuld/eigen vermogen-ratio van AUROPHARMA is de afgelopen 5 jaar gedaald van 50.1% naar 22.3%.

Schuldendekking: De schuld van AUROPHARMA wordt goed gedekt door de operationele kasstroom ( 36.6% ).

Rentedekking: De rentebetalingen op de schuld van AUROPHARMA worden goed gedekt door EBIT ( 139.5 x dekking).

Aurobindo Pharma Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Here's Why Aurobindo Pharma (NSE:AUROPHARMA) Can Manage Its Debt Responsibly

Aurobindo Pharma (NSE:AUROPHARMA) Has A Pretty Healthy Balance Sheet

Is Aurobindo Pharma (NSE:AUROPHARMA) A Risky Investment?

Aurobindo Pharma (NSE:AUROPHARMA) Seems To Use Debt Quite Sensibly

We Think Aurobindo Pharma (NSE:AUROPHARMA) Can Stay On Top Of Its Debt

Recent updates

Aurobindo Pharma Limited Receives USFDA Approval for Cephalexin Tablets USP, 250 Mg and 500 Mg

Aurobindo Pharma Limited (NSEI:AUROPHARMA) entered into a binding agreement to acquire remaining 49% stake in Gls Pharma Limited from Suresh Pathak and his family members for approximately INR 225 million.

Eugia Steriles Private Limited Receives Its First Product Approval by the United States Food and Drug Administration

Estimating The Intrinsic Value Of Aurobindo Pharma Limited (NSE:AUROPHARMA)

Aurobindo Pharma Limited Approves Interim Dividend for the Financial Year 2023-24

This Is Why Aurobindo Pharma Limited's (NSE:AUROPHARMA) CEO Can Expect A Bump Up In Their Pay Packet

Price target increased by 12% to ₹1,503

Earnings Update: Here's Why Analysts Just Lifted Their Aurobindo Pharma Limited (NSE:AUROPHARMA) Price Target To ₹1,422

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Aurobindo Pharma Limited, Annual General Meeting, Aug 29, 2024

Aurobindo Pharma Limited (NSEI:AUROPHARMA) announces an Equity Buyback for 5,136,986 shares, representing 0.88% for INR 7,500 million.

Now 20% overvalued after recent price rise

Here's Why Aurobindo Pharma (NSE:AUROPHARMA) Can Manage Its Debt Responsibly

Price target increased by 7.9% to ₹1,292

Aurobindo Pharma Limited (NSE:AUROPHARMA) Released Earnings Last Week And Analysts Lifted Their Price Target To ₹1,271

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value

Now 21% overvalued after recent price rise

Aurobindo Pharma Limited's (NSE:AUROPHARMA) Earnings Are Not Doing Enough For Some Investors

Aurobindo Pharma Limited Announces Retirement of K. Ragunathan as Chairman of Board of Directors, Effective March 31, 2024

Aurobindo Pharma Limited Appoints N. Ravikiran as Chief Business Officer

Insider recently sold ₹2.1m worth of stock

Less than half of directors are independent

Dividend reduced to ₹1.50

Aurobindo Pharma Limited Receives USFDA Approval for Deflazacort Tablets, 6 mg, 18 mg, 30 mg, and 36 mg

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Aurobindo Pharma Limited Approves the Resignation of Dr.(Mrs.) Avnit Bimal Singh as an Independent Director

Price target increased by 7.6% to ₹1,087

Price target increased by 7.5% to ₹1,085

Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Worth ₹1.1k Based On Its Intrinsic Value?

Price target increased by 7.2% to ₹1,071

Insider recently sold ₹9.7m worth of stock

Aurobindo Pharma (NSE:AUROPHARMA) Has A Pretty Healthy Balance Sheet

Insider recently sold ₹1.6m worth of stock

New minor risk - Insider selling

Price target increased by 10% to ₹956

Upcoming dividend of ₹3.00 per share at 0.3% yield

Aurobindo Pharma Limited Approves First Interim Dividend, Payable on or Before December 4, 2023

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Associate President of RAD- II recently sold ₹1.6m worth of stock

Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value

Aurobindo Pharma Limited Announces Interim Dividend for the Financial Year 2022-23

Price target increased by 8.2% to ₹721

Aurobindo Pharma Limited Announces Resignation of M. Sivakumaran as Whole-Time Director and Director

Full year 2023 earnings: EPS misses analyst expectations

Aurobindo Pharma Limited to Report Q2, 2024 Results on Nov 14, 2023

Aurobindo Pharma Limited Receives USFDA Approval for Saxagliptin Tablets, 2.5 Mg and 5 Mg

Aurobindo Pharma Limited, Annual General Meeting, Aug 25, 2023

Aurobindo Pharma Limited Announces Completion of US Fda Inspection At Unit III At Bachupally Village, Medchal Malkajgiri District, Telangana

Aurobindo Pharma Limited Announces Classification of US FDA Inspection At Unit XIV, Anakapalli District, Andhra Pradesh

Is Aurobindo Pharma (NSE:AUROPHARMA) A Risky Investment?

Price target increased by 9.0% to ₹643

Full year 2023 earnings: EPS misses analyst expectations

Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Trading At A 29% Discount?

Insider recently sold ₹1.3m worth of stock

Insider recently bought ₹3.2m worth of stock

Aurobindo Pharma Limited's (NSE:AUROPHARMA) Intrinsic Value Is Potentially 93% Above Its Share Price

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Aurobindo Pharma Limited Approves First Interim Dividend, Payable on or Before March 3, 2023

Aurobindo Pharma (NSE:AUROPHARMA) Seems To Use Debt Quite Sensibly

Aurobindo Pharma Limited Announces Completion Of US FDA Inspection At Unit IX - Reg

Consensus EPS estimates fall by 15%

Price target decreased to ₹621

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Is There An Opportunity With Aurobindo Pharma Limited's (NSE:AUROPHARMA) 50% Undervaluation?

Insider recently sold ₹11m worth of stock

Insider recently sold ₹2.7m worth of stock

Aurobindo Pharma Limited (NSEI:AUROPHARMA) completed the acquisition of 34% stake in GLS Pharma Ltd from Suresh and Sunita Pathak.